Stories
Prime pharmacists address AMCP virtual conference as keynote speakers
Catherine Starner, PharmD and Nicole Kjesbo, PharmD discuss the specialty drug pipeline and forecast
April 23, 2021To determine the pipeline and forecast, Starner and Kjesbo consider cost, population/prevalence and management strategies – such as utilization management, prior authorizations and quantity limits. For inclusion on the Watch List, Prime generally focuses on drugs that are submitted to the U.S. Food and Drug Administration (FDA) and have a high anticipated spend based on per member per month (PMPM). Prime forecasts drugs on both medical and pharmacy benefits to help manage total drug spend for its health plan clients.
Starner and Kjesbo focused on pipeline and forecasting for:
While gene therapy approvals have been few and far between, there are more on the horizon. Possible gene therapy reviews include:
- Eladocagene exuparvovec, PTC Therapeutics – aromatic l-amino acid decarboxylase (AADC) deficiency
- SRP-9001, Sarepta Therapeutics – Duchenne muscular dystrophy (DMD)
- AMT-061 (etranacogene dezaparvovec), uniQure – hemophilia B
Prime publishes monthly decisions expected from the FDA and monthly pipelines.
Related news
Stories
March 9, 2023
Prime Together Foundation supports Casa Esperanza, New Mexico’s House of Hope
The Prime Together Foundation awarded a grant to Casa Esperanza, New Mexico’s House…
Stories
February 15, 2023
Prime’s SIU team tracking the rise of drug-related schemes on social media
By Jessica Johnson, SIU Clinical Consultant, Prime Therapeutics Discourse on the promises and…
Stories
February 14, 2023
The Healthcare Businesswomen’s Association Rochester chapter honors Dr. Marci Chodroff with Everest Award for exemplary volunteer service
The Healthcare Businesswomen’s Association (HBA) Rochester chapter recognized Marci J Chodroff, MD, FACP,…